Haptoglobin serves as an antioxidant by virtue of its ability to prevent hemoglobin-driven oxidative tissue damage. It was recently demonstrated that an allelic polymorphism in the haptoglobin gene is predictive of the risk for numerous microvascular and macrovascular diabetic complications. Because these complications are attributed in large part to an increase in oxidative stress, a study was conducted to determine whether the different protein products of the 2 haptoglobin alleles differed in the antioxidant protection they provided. A statistically significant difference was found in the antioxidant capacity of purified haptoglobin produced from the 2 different alleles, consistent with the hypothesis that differences in genetically determined antioxidant status may explain differential susceptibility to diabetic vascular complications. These differences may be amplified in the vessel wall because of differences in the sieving capacity of the haptoglobin types. Therefore, an attempt was made to identify the minimal haptoglobin sequences necessary to inhibit oxidation by hemoglobin in vitro, and 2 independent haptoglobin peptides that function in this fashion as efficiently as native haptoglobin were identified. Identification of the biochemical basis for differences among haptoglobin types may lead to the rational development of new pharmacologic agents, such as the mini-haptoglobin described here, to avert the development of diabetic vascular complications. (Blood. 2001;98:3693-3698)

Introduction

Haptoglobin is a serum protein that functions as an antioxidant by virtue of its ability to bind to hemoglobin and thereby to prevent the oxidative tissue damage that may be mediated by free hemoglobin. The importance of this protective mechanism has been demonstrated in haptoglobin knockout mice in which a marked increase in oxidative tissue damage develops in response to hemolysis. In humans, 2 alleles (denoted 1 and 2) exist for the haptoglobin gene. Biophysical and biochemical properties of the haptoglobin polymeric molecules resulting from the 3 possible combinations (haptoglobin 1-1, 2-1, or 2-2) of these 2 alleles are dramatically different.

We have recently found in multiple independent studies (and in A.P.L. et al, manuscript submitted for publication) of more than 1000 persons in Israel, Belgium, and the United States that the haptoglobin phenotype is a predictor of the risk for microvascular and macrovascular complications of diabetes. Specifically, diabetic patients with the haptoglobin 1-1 phenotype were shown to be remarkably resistant to the development of diabetic retinopathy, diabetic nephropathy, and cardiovascular disease. Moreover, we found that a graded effect was evident with regard to risk and to the number of haptoglobin 2 alleles. For example, in a prospective study of incident cardiovascular disease, we found that participants homozygous for the haptoglobin 2 allele had a 5-fold increase in the risk for cardiovascular disease compared with patients homozygous for the haptoglobin 1 allele, whereas heterozygotes were found to have an intermediate risk (A.P.L. et al, manuscript submitted for publication).

It has been proposed that an increase in oxidative stress plays a crucial role in the development of diabetic vascular complications. Accordingly, differences in genetically endowed antioxidant status may confer increased or decreased susceptibility to the development of these diabetic vascular complications. We demonstrate here that purified haptoglobin 1-1 is a superior antioxidant to purified haptoglobin 2-2 in vitro. A key site of action of haptoglobin in neutralizing the oxidative capacity of hemoglobin is the extravascular space, particularly after endothelial injury. Haptoglobins 1-1 and 2-2 clearly differ in their ability to sieve into the extravascular compartment across the endothelial cell barrier. Because this difference in sieving is almost certainly a reflection of the profound differences in the sizes of haptoglobin 1-1 dimers and haptoglobin 2-2 cyclic polymers, we sought to identify a minimal haptoglobin peptide with preserved antioxidant function that would have an improved ability to penetrate the extravascular space. We describe identification of 2 distinct haptoglobin peptides, each of which can function as efficiently as haptoglobin in preventing oxidation by hemoglobin in vitro.

Materials and methods

Oxidation of linolenic acid by hemoglobin

All reagents were from Sigma Israel (Rehovot) unless otherwise indicated. Fatty acid micelles were prepared by adding 1 μM linolenic acid to 1 mL buffer A (50 mM Tris HCl, pH 6.5) and vortexing vigorously for 10
Table 1. Primer sequences used for cloning haptoglobin β and α subunit constructs

<table>
<thead>
<tr>
<th>No.</th>
<th>Primer name</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F-β-1</td>
<td>5′-GCGGATACCTCCTGTTGGAACCTCTGAAGTC-3′</td>
</tr>
<tr>
<td>2</td>
<td>R-β-245</td>
<td>5′-GGGCAACCTTCTCTCTCATGCTCTGAAAGC-3′</td>
</tr>
<tr>
<td>3</td>
<td>F-β-80</td>
<td>5′-GCGGATACCTCCTGTTGGAACCTCTGAAGTC-3′</td>
</tr>
<tr>
<td>4</td>
<td>R-β-161</td>
<td>5′-GCGGATACCTCCTGTTGGAACCTCTGAAGTC-3′</td>
</tr>
<tr>
<td>5</td>
<td>F-β-120</td>
<td>5′-GCGGATACCTCCTGTTGGAACCTCTGAAGTC-3′</td>
</tr>
<tr>
<td>6</td>
<td>F-α-1</td>
<td>5′-GCGGATACCTCCTGTTGGAACCTCTGAAGTC-3′</td>
</tr>
<tr>
<td>7</td>
<td>R-α-70,129</td>
<td>5′-GCGGATACCTCCTGTTGGAACCTCTGAAGTC-3′</td>
</tr>
</tbody>
</table>

bp indicates base pair.

Table 2. Primer pairs and deduced product sizes

<table>
<thead>
<tr>
<th>RHp no.</th>
<th>Haptoglobin subunit</th>
<th>Forward primer</th>
<th>Reverse primer</th>
<th>DNA fragment size, bp</th>
<th>Protein size, amino acids</th>
<th>Fusion protein size, kd</th>
</tr>
</thead>
<tbody>
<tr>
<td>RHp1</td>
<td>β</td>
<td>1</td>
<td>2</td>
<td>725</td>
<td>245</td>
<td>66.0</td>
</tr>
<tr>
<td>RHp2</td>
<td>β</td>
<td>3</td>
<td>4</td>
<td>243</td>
<td>83</td>
<td>39.2</td>
</tr>
<tr>
<td>RHp3</td>
<td>β</td>
<td>5</td>
<td>6</td>
<td>123</td>
<td>41</td>
<td>32.7</td>
</tr>
<tr>
<td>R Hp4</td>
<td>β</td>
<td>7</td>
<td>8</td>
<td>60</td>
<td>20</td>
<td>29.3</td>
</tr>
<tr>
<td>RHp5</td>
<td>α</td>
<td>7</td>
<td>8</td>
<td>367</td>
<td>129</td>
<td>42.0</td>
</tr>
<tr>
<td>RHp6</td>
<td>α</td>
<td>7</td>
<td>8</td>
<td>210</td>
<td>70</td>
<td>34.9</td>
</tr>
</tbody>
</table>

SEM was determined.
amino acids of the constructs were made as described in "Materials and methods" and correspond to the 
are truncated mutants of the monomer. The 2 alleles for haptoglobin differ only in their 
a chain, as shown. RHp1 is the entire β-chain. RHp2 to RHp4 are truncated mutants of the β-chain. RHp5 is the α-chain from the 2 allele, and RHp6 is the α-chain from the 1 allele.

1:2000 dilution for overnight incubation at room temperature. This antihemoglobin antibody was then removed, and the wells were washed 5 times with TBS and incubated with antirabbit alkaline phosphatase–conjugated secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA) at a 1:2000 dilution. After again washing the wells 5 times, p-nitrophenyl phosphate (Sigma, Rehovot, Israel) was added according to the manufacturer’s protocol, and the absorbance at 405 nM was recorded over time. GST alone or TBS alone was used as a negative control, and haptoglobin purified from human serum was used as a positive control. In this qualitative assay, binding was categorized as 0 (not significantly different from TBS or GST), 2+ if significant binding was present using less than 10 μg recombinant protein, and 1+ if significant binding was present only when using more than 100 μg recombinant protein in the assay.

Antioxidant activity of truncated haptoglobin

Recombinant GST-fusion proteins were analyzed in the linolenic acid oxidation assay for their ability to inhibit the oxidation of linolenic acid by hemoglobin as described above. GST alone had no effect on the oxidation of linolenic acid by hemoglobin even when used at concentrations 10 times greater than that used for the recombinant GST-haptoglobin fusion proteins.

Results

Inhibition of oxidation of linolenic acid by purified haptoglobin

As previously demonstrated, we found that hemoglobin can oxidize linolenic acid in a time-dependent fashion as assessed using conjugated diene (A232) formation (Figure 2A). This oxidation of linolenic acid by hemoglobin was shown to be inhibited by stoichiometric amounts of a mixture of haptoglobin proteins prepared from pooled human sera.13 We sought to determine whether the ability to inhibit the oxidation of LDL by hemoglobin was different between haptoglobin 1-1 and 2-2 proteins. Figure 3A provides a representative example of the differences in TBARS formation produced by the oxidation of LDL in the presence of no haptoglobin and in the greater protection against linolenic oxidation than haptoglobin 2-2 (Figure 2B). The percentage inhibition of the hemoglobin-induced oxidation of linolenic acid by both haptoglobin type 1-1 and haptoglobin type 2-2 was linearly related to the concentration of haptoglobin in our assay over a range of haptoglobin concentrations, from approximately 0.1 to 0.7 μM. Over this concentration range, haptoglobin 1-1 consistently demonstrated more inhibition of oxidation of linolenic acid than haptoglobin 2-2 (Figure 2B). At haptoglobin concentrations greater than 1.0 μM, there was complete (100%) inhibition of linolenic acid oxidation by both types of haptoglobin, whereas at haptoglobin concentrations less than 0.1 μM, there was no significant inhibition of linolenic acid oxidation by either type of haptoglobin.

Inhibition of low-density lipoprotein oxidation by haptoglobin

As previously demonstrated,13 we found that hemoglobin can oxidize LDL in a time-dependent fashion as assessed by measuring TBARS (Figure 3A). This oxidation of LDL by hemoglobin was previously shown to be inhibited by stoichiometric amounts of a mixture of haptoglobin proteins prepared from pooled human sera.13 We sought to determine whether the ability to inhibit the oxidation of LDL by hemoglobin was different between haptoglobin 1-1 and 2-2 proteins. Figure 3A provides a representative example of the differences in TBARS formation produced by the oxidation of LDL in the presence of no haptoglobin and in the
presence of haptoglobin 1-1 or haptoglobin 2-2, each at a concentration of 5 μM haptoglobin. At this haptoglobin concentration, haptoglobin 1-1 provided statistically significant greater protection against LDL oxidation than haptoglobin 2-2 (Figure 3B). The percentage inhibition of the haptoglobin-induced oxidation of LDL by haptoglobin 1-1 or 2-2 was linearly related to the concentration of haptoglobin in the assay over a range of haptoglobin concentrations, from 1 to 20 μM. Over this concentration range, haptoglobin 1-1 consistently demonstrated greater inhibition of oxidation of LDL than haptoglobin 2-2 (Figure 3B). Outside this concentration range for haptoglobin, where either haptoglobin was present in extreme molar excess or haptoglobin was used at the concentrations shown, data are expressed as a percentage of inhibition of the amount of TBARS observed with haptoglobin 1-1. The excess free haptoglobin 2-2 would be expected to result in more oxidation of LDL or linolenic acid than what was observed with haptoglobin 1-1.

To investigate the effective hemoglobin-binding capacity of our haptoglobin 1-1 and 2-2 preparations, we developed a filtration assay designed to monitor the amount of unbound hemoglobin, as described in “Materials and methods.” The filtration assay used the Centricon microfiltration system by way of a membrane with a 100-kd cutoff. Haptoglobin and hemoglobin were mixed together at the same molar ratios used in the oxidation studies described above and then were subjected to Centricon ultrafiltration. The amount of free or unbound hemoglobin was determined spectrophotometrically in the ultrafiltrate. If the greater amount of oxidation in the reactions involving haptoglobin 2-2 was attributed to less hemoglobin-binding capacity than those involving haptoglobin 1-1, we would have expected to see more free hemoglobin in the ultrafiltrate when using haptoglobin 2-2. This was not the case. There was no significant difference in the free hemoglobin concentrations in the ultrafiltrate of haptoglobin 1-1–hemoglobin solutions than in haptoglobin 2-2–hemoglobin solutions. At a concentration of 10 μM hemoglobin and 5 μM haptoglobin (concentrations at which we found haptoglobin 1-1 was significantly superior to haptoglobin 2-2 in protecting against hemoglobin-induced LDL oxidation), we found that the molar ratio of free hemoglobin in the ultrafiltrate for haptoglobin 1-1–hemoglobin solutions compared to haptoglobin 2-2–hemoglobin solutions was 1.09 ± 0.15 (P = .835; n = 6). Therefore, the inferior antioxidant capacity of our preparation of haptoglobin 2-2 could not be explained by a lower effective hemoglobin-binding capacity than our preparation of haptoglobin 1-1.

Identification of putative hemoglobin-binding sites on haptoglobin by ELISA using truncated haptoglobin

The haptoglobin-haptoglobin complex has not as yet been crystallized; thus, the residues involved in binding are not definitively known. Findings from gel permeation studies with purified haptoglobin have suggested that the β-chain of haptoglobin is responsible for binding to hemoglobin. The importance of several residues in the β-chain has been suggested by the use of proteolytic peptides of haptoglobin and the ascertainment of their ability to bind to hemoglobin in native polyacrylamide gels. Further assessment of the putative residues on haptoglobin capable of binding to hemoglobin using recombinant haptoglobin-truncated mutants or haptoglobin peptides has not been performed. Therefore, we developed a simple ELISA capable of differentiating qualitative differences in the binding of haptoglobin to hemoglobin. A battery of α- and β-chain recombinant fusion proteins was made and is shown schematically in Figure 1. We were able to identify binding not only in the β-chain but, surprisingly, also in the α-chain (qualitatively denoted by 0-2+ binding in Table 3). This assay was only used to detect the presence or absence of binding of

\[
\text{Figure 3. Oxidation of LDL by hemoglobin. (A) Standard reaction demonstrating the time-dependent increase in TBARS formation when LDL is incubated with hemoglobin (10 μM) in the presence of no haptoglobin, haptoglobin 1-1 (5 μM), or haptoglobin 2-2 (5 μM) as described in "Materials and methods." Data shown are the mean ± SEM for 4 independent experiments. (B) Comparison of the ability to inhibit the hemoglobin-induced oxidation of LDL by haptoglobin 1-1 or 2-2. Hemoglobin was used at a concentration of 10 μM, and haptoglobin was used at the concentrations shown. Data are expressed as a percentage of inhibition of the amount of TBARS obtained in the absence of any haptoglobin over the entire incubation period by integrating the area under the TBARS versus the time curve using MATLAB, as described in "Materials and methods." Data shown are the mean ± SEM of 4 independent experiments for each haptoglobin concentration. *Difference in the mean percentage inhibition between haptoglobin 1-1 and haptoglobin 2-2 was statistically significant (P < .004).}
\]
specific haptoglobin mutants before ascertaining whether they had activity as antioxidants and could not be used to demonstrate quantitative differences in binding affinity between the different mutants.

Truncated haptoglobin can prevent the oxidation of linolenic acid by hemoglobin. We tested the ability of the truncated haptoglobin fusion proteins that were shown to bind to hemoglobin in the ELISA for their ability to inhibit the oxidation of linolenic acid by hemoglobin as described in “Materials and methods.” Using progressive deletion analysis, we were able to identify in the β-chain an 81–amino acid fragment (construct recombinant haptoglobin 2 [RHp2], Table 2) that could completely prevent the oxidation of linolenic acid by hemoglobin at concentrations of 0.18 μM based on Bradford protein assay (Figure 4A), suggesting that this truncated construct is at least as potent in inhibiting the oxidation of linolenic acid by haptoglobin as native haptoglobins. A 40–amino acid fragment within this 81–amino acid fragment could not inhibit the oxidation of linolenic acid, even though it demonstrated specific binding to hemoglobin (Figure 4B, Table 3). We were also able to demonstrate that the α-chain of haptoglobin (RHp 5 or 6, corresponding to the α-chain from allele 1 or 2) can inhibit oxidation by hemoglobin as efficiently as haptoglobin (data not shown).

Table 3. Binding of truncated haptoglobin to hemoglobin

<table>
<thead>
<tr>
<th>Substrate</th>
<th>RHp1</th>
<th>RHp2</th>
<th>RHp3</th>
<th>RHp4</th>
<th>RHp5</th>
<th>RHp6</th>
</tr>
</thead>
<tbody>
<tr>
<td>TBS</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>++</td>
</tr>
<tr>
<td>GST</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

RHp indicates recombinant haptoglobin; GST, glutathione-S-transferase; and TBS, Tris-buffered saline.

Discussion

We have demonstrated that there are functional differences in the antioxidant capacity of the different haptoglobin proteins toward hemoglobin, suggesting that those with haptoglobin 1-1 protein may have superior antioxidant protection than those with haptoglobin 2-2 protein. These data are consistent with earlier findings showing that the consumption of vitamin C in the plasma in vitro of persons with haptoglobin 2-2 was more rapid than in the plasma of those with haptoglobin 1-1 and that vitamin C levels are significantly lower in those with haptoglobin 2-2.22

The stoichiometries of haptoglobin 1-1 and 2-2 binding to hemoglobin are identical.1,18,19 Our results showing a difference between the amount of hemoglobin-inducible oxidation between our 2 different preparations was not caused by a systematic error in the determination of the hemoglobin-binding capacity of our preparations of the 2 haptoglobin types. Using concentrations of haptoglobin and hemoglobin identical to what was used in the oxidation reactions described in this study, we found that there was no significant difference between the amount of free hemoglobin using our haptoglobin 1-1 preparations and our haptoglobin 2-2 preparations. This was important to demonstrate because if our haptoglobin 2-2 had lower hemoglobin-binding capacity than our haptoglobin 1-1, the amount of free hemoglobin available to oxidize linolenic acid or LDL in the oxidation reactions using haptoglobin 2-2 would have been greater. Therefore, the inferior antioxidant capacity of our haptoglobin 2-2 could not be attributed to lower hemoglobin-binding capacity.
The antioxidant activity of haptoglobin results, at least in part, from the binding of haptoglobin to hemoglobin, thereby preventing the dissociation of ferric heme from globin.\textsuperscript{23} Demonstration that iron is one of the species directly responsible for the oxidation of linolenic acid has been demonstrated by 2 groups using the iron chelator, desferrioxamine.\textsuperscript{16,17} However, Gutteridge\textsuperscript{16} has also shown that hemoglobin is capable of stimulating lipid peroxidation for a short period of time by a reaction independent of free heme (ie, inhibited by haptoglobin but not inhibited by desferrioxamine) and that heme release only occurs after the products of lipid peroxidation damage the hemoglobin molecule, causing it to release iron. 

The difference between haptoglobin 1-1 and 2-2 in inhibiting the oxidation of linolenic acid, according to these mechanistic schemes, may be the result of differences in the ability of the different types of haptoglobin to prevent the release of heme. We have not observed that the differences between the 2 types of haptoglobin are more exaggerated at earlier time points in the oxidation reaction, which might have suggested that the alternative mechanism proposed by Gutteridge\textsuperscript{16} is a point of difference between the 2 types of haptoglobin. The haptoglobin-hemoglobin complex has been demonstrated to have a potent peroxidase activity\textsuperscript{24} that could also serve as a point of difference between the 2 haptoglobin types and could provide an explanation for their differences in apparent antioxidant activity.

The statistically significant but relatively modest differences we have described here in antioxidant capacity between the different haptoglobin types may be dramatically amplified in vivo because of differences in the ability of the different haptoglobin types to gain access to the vessel wall. A schematic drawing of the different haptoglobin polymers,\textsuperscript{25} in persons with haptoglobin 1-1 or 2-2, as shown in Figure 5, demonstrates the large differences in size between the different haptoglobin types likely to account for these differences in sieving capacity. At sites of blood vessel injury (ie, after coronary angioplasty), there is a sudden release of free hemoglobin into the blood vessel wall. Haptoglobin is not normally found in appreciable concentrations in the normal vessel wall. Therefore, the ability of haptoglobin to sieve into the vessel wall to neutralize hemoglobin is likely to be of great importance. In the patient with diabetes, already burdened with increased oxidative stress from hyperglycemia,\textsuperscript{9,10} differences in genetically determined endogenous antioxidant protection may have exaggerated importance.

We have identified 2 peptides derived from haptoglobin that can independently bind to hemoglobin and prevent it from oxidizing substrate, analogous to the full-length haptoglobin molecule. We have not determined the affinity of these constructs for hemoglobin, nor have we demonstrated that the stoichiometry of binding of these constructs is identical to native haptoglobin. Our studies suggest that these truncated haptoglobins are similar in their potency to native haptoglobin in terms of their ability to inhibit the oxidation of linolenic acid by hemoglobin. Such a mini-haptoglobin may be expected to have improved access to the extravascular space and thus may be proposed as a candidate drug in animal models of diabetic vascular complications. We are performing progressive truncation of these mini-haptoglobins to define the absolute minimal haptoglobin that can inhibit oxidation by hemoglobin.

We have learned from epidemiologic studies that haptoglobin type is fundamentally important in the development of diabetic vascular disease. Elucidation of the biochemical basis for differences between the haptoglobin types is the first step necessary for the development of new drugs and strategies to limit diabetic vascular complications.

References